The Potential for Postrandomization Confounding in Randomized Clinical Trials.
Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
JoAnn E
JE
Manson
Barbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute, Los Angeles, California.
Chrisandra L
CL
Shufelt
Departments of Biostatistics and Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
James M
JM
Robins
D008078:Cholesterol, LDL / Q000097:blood*; D015986:Confounding Factors, Epidemiologic; D003324:Coronary Artery Disease / Q000453:epidemiology / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D015994:Incidence; D008525:Medroxyprogesterone / Q000008:administration & dosage; D064792:Pragmatic Clinical Trials as Topic; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control*; D016896:Treatment Outcome
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008525:Medroxyprogesterone